Inspire Medical (INSP) Q2 2025: Inspire 5 Transition Drives 4% Guidance Cut, Sets Stage for 20%+ Center Throughput Gains
Inspire Medical’s Q2 marked a pivotal reset as execution hurdles in the Inspire 5 rollout led to a 4% revenue guidance cut, but the company’s operational investments and early pilot data point to a meaningful throughput uplift in 2026 and beyond. Management is betting on new reimbursement, streamlined procedures, and expanded marketing to reignite growth after a transition-heavy year, while investors must weigh the near-term disruption against emerging capacity and adoption levers.
Summary
- Rollout Friction: Transition delays for Inspire 5 and Medicare billing bottlenecks dominated H1 execution.
- Capacity Catalyst: Early-adopter centers saw over 20% implant growth, highlighting throughput potential post-transition.
- 2026 Setup: Management is investing in marketing, digital tools, and center expansion to drive an expected growth reacceleration next year.
Performance Analysis
Inspire Medical’s Q2 performance reflected a business in operational transition, with revenue growth moderating as the Inspire 5, next-generation sleep apnea implant, rollout met real-world onboarding friction. U.S. revenue, which constitutes the vast majority of the business, grew at a slower pace than prior periods, as most implants in the quarter were still Inspire 4 units. The company cited training, IT integration (notably SleepSync, cloud-based patient management), and delayed Medicare billing software as the two main bottlenecks limiting Inspire 5 adoption and thus overall volume growth. International revenue grew faster but remains a small percentage of the business.
Margin dynamics were pressured by a $2.1 million charge for excess Inspire 4 subcomponents, which reduced gross margin by 100 basis points, while operating expenses rose 15% due to expanded salesforce, higher marketing, and a one-time stock-based comp charge. The company reported an operating loss and a net loss for the quarter, but adjusted EBITDA improved 14% year-over-year, with a stable 20% margin, reflecting underlying cost discipline outside of transition-related items.
- Inventory Overhang: Inspire 4 inventory “burndown” will remain a headwind in H2, as centers transition to the new device.
- Expense Uplift: DTC (direct-to-consumer) marketing spend is ramping over 20% YoY, with a $115 million full-year target to build pipeline and awareness.
- Adjusted Profitability: Despite GAAP losses, adjusted net income per share rose 40% YoY, showing underlying business strength when transition costs are excluded.
While near-term disruption is clear, the company’s cash position remains robust at $411 million, supporting continued investment in market development and infrastructure.
Executive Commentary
"As the quarter progressed, we encountered certain headwinds that slowed our efforts to transition customers to Inspire 5. While we are disappointed with the elongated timeframe we now expect for the rollout, we remain focused on advancing the transition of our customers to Inspire 5."
Tim Herbert, Chairman and Chief Executive Officer
"The most significant item [in the EPS guide change] is just the gross margin that we're going to, the reduced gross margin that we would obtain had we had higher revenue. So really the biggest impact there is the reduction of the revenue guide from our previous midpoint... but we are also increasing our DTC spend too."
Rick Buhols, Chief Financial Officer
Strategic Positioning
1. Inspire 5 Rollout: Unlocking Center Capacity
The Inspire 5 system, which eliminates the need for a pressure-sensing lead and integrates SleepSync, is central to the company’s next phase of growth. Early clinical data and pilot center results show more than 20% increase in patient implants, driven by reduced surgical complexity and shorter procedure times. However, the transition has been hampered by IT onboarding delays and the need for Medicare billing updates, both of which are now being aggressively addressed.
2. Payer and Reimbursement Tailwinds
Medicare reimbursement for the new CPT code 64568 is now live, with proposed 2026 rules calling for a $1,300 (4-5%) increase in hospital and ASC rates. This removes a major procedural bottleneck and supports higher utilization, especially as 90% of covered lives are now eligible for the new code. Management sees this as a key enabler for broader adoption and improved center economics.
3. Marketing and Footprint Expansion
After intentionally pausing patient marketing and new center launches in H1 to focus on Inspire 5 transition, the company has now resumed direct-to-consumer campaigns and territory expansion. Website activity, patient calls, and provider appointments are already trending up, with new field clinical reps and digital scheduling expected to further build the pipeline in H2 and 2026.
4. Digital Tools and Clinical Evidence
SleepSync, the cloud-based patient management system, is being positioned as a long-term differentiator, enabling remote monitoring and programming for improved outcomes. The company is also advancing its predictor algorithm (BMI and neck circumference-based) to potentially eliminate the DICE procedure for most patients, streamlining eligibility and expanding the addressable market.
5. Channel Diversification and Provider Training
Management is targeting expanded provider capacity by certifying new surgeons, re-engaging previously reluctant ENTs, and exploring adoption by oral and general surgeons. Training and onboarding are being accelerated to ensure that the Inspire 5 platform’s benefits translate into higher throughput across the network.
Key Considerations
This quarter marked a transition phase for Inspire Medical, with operational friction and delayed adoption weighing on near-term results but laying the groundwork for a stronger growth profile post-transition. Investors should weigh the following:
- Transition Bottlenecks: The Inspire 5 launch was slowed by IT onboarding (SleepSync), Medicare billing delays, and center training—these are now being systematically addressed.
- Inventory Dynamics: Inspire 4 inventory “burndown” will continue to weigh on H2 results, but is expected to normalize as more centers convert to Inspire 5.
- Marketing Leverage: Resumed DTC spend and center expansion are designed to reignite patient flow and offset any lingering GLP-1 or patient deferral impacts.
- Clinical and Reimbursement Tailwinds: Proposed Medicare rate increases and positive clinical data for Inspire 5 should support both adoption and margin expansion in 2026.
Risks
Execution risk remains elevated in the near term, as full Inspire 5 transition and SleepSync onboarding must be completed across the network to realize expected volume and margin benefits. Any further delays in training, IT integration, or reimbursement policy shifts could prolong disruption. Patient adoption may also be influenced by ongoing GLP-1 trends and competitive responses, while inventory management and center activation rates will be critical to watch in H2 and 2026.
Forward Outlook
For Q3 2025, Inspire Medical guided to:
- Sequential revenue growth of 1% to 3% as Inspire 5 transition progresses
For full-year 2025, management lowered guidance:
- Revenue of $900 to $910 million (12% to 13% YoY growth)
- Diluted net income per share of $0.40 to $0.50 (down from $2.20 to $2.30 previously)
Management highlighted several factors that shape the outlook:
- Majority of SleepSync implementations targeted for completion by end of Q3
- Medicare billing and reimbursement now fully live, expected to unlock pent-up demand in H2
- Seasonal Q4 volume step-up expected, in line with historical patterns
Takeaways
Inspire Medical is navigating a challenging but temporary operational reset, with short-term disruption from Inspire 5 transition offset by strong evidence of future capacity and adoption gains. Investors should watch for execution milestones on SleepSync, marketing ROI, and center activation as leading indicators for a 2026 growth reacceleration.
- Execution Reset: Near-term headwinds from onboarding and inventory are clear, but early Inspire 5 data validates the underlying growth thesis.
- Margin and Profitability: Transition costs and higher OpEx will weigh on 2025 results, but adjusted metrics and cash position support continued investment.
- Growth Inflection: The stage is set for a return to higher growth rates post-transition, provided execution on digital, marketing, and center expansion stays on track.
Conclusion
Inspire Medical’s Q2 was defined by transition pain and a necessary guidance reset, but the company’s operational investments and Inspire 5-enabled throughput gains point to a stronger growth profile once execution bottlenecks are cleared. Investors must balance near-term disruption with the potential for sustained adoption and margin tailwinds in 2026 and beyond.
Industry Read-Through
This quarter underscores the operational complexity of large-scale next-generation device rollouts in medtech, especially when IT integration and reimbursement changes are required. Other device companies planning major platform transitions should note the need for robust onboarding resources, payer alignment, and staged marketing investment to avoid volume and margin air pockets. The positive early data on capacity gains and streamlined procedures also highlights the competitive advantage for companies that can deliver both clinical and operational value to provider networks.